Key facts
- It has raised $5.5M; the latest was Seed Round ($5.5M) in Apr 2026.
- Notable investors include Lifeline Ventures, Aalto Start-Up Center, VTT Technical Research Centre of Finland, Cloudberry Pioneer Investments.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Proteins.1
- ·The full record, as it builds
Funding rounds
No funding rounds for Proteins.1 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Proteins.1
Developer of an ultra sensitive, enzyme free molecular detection platform intended to reveal previously undetectable biological signals. The company has built a physics based multiomics system that works simultaneously across DNA, RNA, and proteins without using enzymes, allowing deeper and earlier protein level detection than conventional methods, enabling biopharmaceutical companies, diagnostics developers, and research institutions to conduct biomarker research, liquid biopsy applications, and next generation diagnostics with improved sensitivity and earlier disease signal detection.
- Sector
- Healthcare
- HQ
- Espoo, Finland
- Founded
- 2025
- Employees
- 3
- Website
- proteins1.com/
- Ownership
- Privately Held (backing)
Proteins.1 doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Proteins.1 shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Proteins.1 in its N-PORT filings yet. We sweep new filings monthly.